Biogen fourth-quarter profit misses on Aduhelm exit costs

Biogen missed Wall Street
estimates for fourth-quarter profit on Tuesday following its
decision last month to return the rights for Alzheimer's disease
drug Aduhelm and on soft sales of multiple...

Related Keywords

Bengaluru , Karnataka , India , Christopher Viehbacher , Manas Mishra , Shounak Dasgupta , Sriparna Roy , Reuters , Wall Street , Markets ,